Nightstar Therapeutics reported a net loss of $7.6 million, or $0.27 per share, for 2018’s third quarter compared with a net loss of $8.2 million, or $0.38 per share, for the same quarter in 2017.
General and administrative costs increased from $2 million to $3 million primarily due to an increase in personnel-related costs to support research and development activities, according to a press release.
Research and development costs increased from $4 million to $7.8 million for the quarter, mostly related to program-related expenses for NSR-REP1 and NSR-RPGR, the company’s product
Uncategorized